Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $45.30 -3.06 (-6.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$45.22▼$49.3650-Day Range$41.33▼$54.0852-Week Range$40.62▼$99.56Volume3.75 million shsAverage Volume2.64 million shsMarket Capitalization$8.36 billionP/E RatioN/ADividend YieldN/APrice Target$85.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside89.4% Upside$85.80 Price TargetShort InterestBearish7.58% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.31Based on 19 Articles This WeekInsider TradingSelling Shares$90,105 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.17) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.62 out of 5 starsMedical Sector82nd out of 936 stocksMedical Laboratories Industry3rd out of 18 stocks 4.5 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.58% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Exact Sciences has recently decreased by 1.62%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 2.4 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search Interest29 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 93% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,105.00 in company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($1.17) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -34.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -34.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesJuly 25 at 8:02 PM | money.usnews.comExact Sciences Corp.July 23 at 2:00 AM | americanbankingnews.comQ2 2024 EPS Estimates for Exact Sciences Co. Decreased by Leerink Partnrs (NASDAQ:EXAS)July 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 22, 2024 | investorplace.comGoldman Sachs Says Buy These 3 Stocks for Double-Digit ReturnsJuly 21, 2024 | finance.yahoo.comGERN Jul 2024 3.000 call (GERN240726C00003000)July 21, 2024 | americanbankingnews.comExact Sciences Co. Forecasted to Earn Q4 2025 Earnings of $0.10 Per Share (NASDAQ:EXAS)July 19, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Exact Sciences Through Analyst InsightsJuly 19, 2024 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Given New $75.00 Price Target at The Goldman Sachs GroupJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…July 17, 2024 | businesswire.comExact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer ScreeningJuly 17, 2024 | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 16, 2024 | insidermonkey.comExact Sciences Corporation (EXAS) Slipped Over Investors’ ConcernsJuly 8, 2024 | fool.comThis Cathie Wood Growth Stock Could Soar by 93%, According to Wall StreetJune 13, 2024 | investorplace.comJefferies Says Buy These 3 Stocks for More Than Double-Digit ReturnsJune 13, 2024 | fool.comIs It Time to Buy May's Worst-Performing Nasdaq Stocks?June 11, 2024 | seekingalpha.comExact Sciences: Still No Reason To OwnJune 3, 2024 | insidermonkey.comIs Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?May 28, 2024 | businesswire.comExact Sciences to Participate in June Investor ConferencesSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)7/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$85.80 High Stock Price Target$121.00 Low Stock Price Target$70.00 Potential Upside/Downside+85.0%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-9.48% Pretax Margin-9.38% Return on Equity-7.12% Return on Assets-3.46% Debt Debt-to-Equity Ratio0.66 Current Ratio1.64 Quick Ratio1.45 Sales & Book Value Annual Sales$2.50 billion Price / Sales3.42 Cash Flow$0.02 per share Price / Cash Flow2,809.63 Book Value$17.39 per share Price / Book2.67Miscellaneous Outstanding Shares184,530,000Free Float182,020,000Market Cap$8.56 billion OptionableOptionable Beta1.22 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHCharles River Laboratories InternationalNYSE:CRLSyneos HealthNASDAQ:SYNHMedpaceNASDAQ:MEDPPPDNASDAQ:PPDView All CompetitorsInsiders & InstitutionsIMA Advisory Services Inc.Bought 1,618 shares on 7/26/2024Ownership: 0.018%AlphaCentric Advisors LLCBought 1,000 shares on 7/26/2024Ownership: 0.016%Harbour Investments Inc.Sold 269 shares on 7/26/2024Ownership: 0.015%Skylands Capital LLCBought 12,350 shares on 7/26/2024Ownership: 0.007%AustralianSuper Pty LtdBought 2,773 shares on 7/26/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $73.98 at the beginning of 2024. Since then, EXAS stock has decreased by 38.8% and is now trading at $45.30. View the best growth stocks for 2024 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) posted its earnings results on Wednesday, May, 8th. The medical research company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). The medical research company earned $637.52 million during the quarter, compared to analysts' expectations of $624.95 million. Exact Sciences had a negative trailing twelve-month return on equity of 7.12% and a negative net margin of 9.48%. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. Does Exact Sciences have any subsidiaries? The following companies are subsidiaries of Exact Sciences: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. Who are Exact Sciences' major shareholders? Top institutional shareholders of Exact Sciences include Baillie Gifford & Co. (0.77%), Sumitomo Mitsui Trust Holdings Inc. (0.62%), ARK Investment Management LLC (0.19%) and DNB Asset Management AS (0.13%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL) and Block (SQ). This page (NASDAQ:EXAS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.